Browsing by Author "Haberal, N."
Now showing 1 - 13 of 13
- Results Per Page
- Sort Options
Item Characteristics of Lgsoc; A Single Center Experience(2017) Akilli, H.; Coban, G.; Kocaman, E.; Haberal, N.; Ayhan, A.; 0000-0002-5240-8441; 0000-0002-3285-5519; 0000-0001-9852-9911; AAX-3230-2020; AAI-9974-2021; AAK-4587-2021; AAJ-5802-2021Item Correlation of Abnormal Cytology with Histological Findings in Colposcopy Guided Biopsy Speciemens(2014) Ayhan, A.; Tuncer, H. A.; Kusu, E.; Dursun, P.; Haberal, N.; https://orcid.org/0000-0002-5434-1025; https://orcid.org/0000-0001-9852-9911; K-1760-2018; AAK-4587-2021Item Cytomegalovirus (CMV) infection induces an angiogenic response through hepatic stellate cells (HSCs) and leads to early post-transplant liver fibrosis (LF) and poor graft survival(2019) Ozdemir, B. H.; Ozgun, G.; Soy, Ayvazoglu E. H.; Haberal, N.; Moray, G.; Haberal, M.Item Cytomegalovirus (CMV) Infection Induces an Angiogenic Response through Hepatic Stellate Cells (HSCs) and Leads to Early Post-Transplant Liver Fibrosis (LF) and Poor Graft Survival.(2019) Ozdemir, B.H.; Ozgun, G.; Soy, E.H. Ayvazoglu; Haberal, N.; Moray, G.; Haberal, M.; 0000-0002-0993-9917; AAC-5566-2019Item Endothelial Cell Cytoskeleton Rearrangement (ECCSKR) and Endothelial to Mesenchymal Transition (EndoMT) in Liver Allografts Following Acute Rejection (AR): Its Significance on the Development of Liver Fibrosis (LT) and Graft Survival.(2019) Ozdemir, B.H.; Ozgun, G.; Soy, E.H. Ayvazoglu; Haberal, N.; Moray, G.; Haberal, M.; 0000-0002-0993-9917; AAC-5566-2019Item Endothelial cell cytoskeleton rearrangement (ECCSKR) and endothelial to mesenchymal transition (EndoMT) in liver allografts following acute rejection (AR): its significance on the liver fibrosis(2019) Ozdemir, B. H.; Ozgun, G.; Soy, Ayvazoglu E. H.; Haberal, N.; Moray, G.; Haberal, M.Item Hepatocyte Growth Factor (HGF) Prevents the Apoptotic and Anti-Angiogenic Effect of Hypercholesterolemia on Hepatocytes in Liver Allografts(2020) Ozdemir, H. B.; Ozgun, G.; Polat, A. Yucel; Haberal, N.; Moray, G.; Haberal, M.; 0000-0002-7528-3557; 0000-0001-9852-9911; 0000-0002-3462-7632; 0000-0003-2498-7287; X-8540-2019; AAK-4587-2021; AAJ-8097-2021; AAE-1041-2021Item Hepatocyte Growth Factor (HGF) Prevents The Apoptotic and Anti-Angiogenic Effect of Hypercholesterolemia on Hepatocytes in Liver Allografts(2021) Ozdemir, B. H.; Ozgun, G.; Polat, Yucel A.; Haberal, N.; Moray, G.; Haberal, M.; https://orcid.org/0000-0002-7528-3557; https://orcid.org/0000-0002-3590-9375; https://orcid.org/0000-0002-3462-7632; X-8540-2019; AAP-3975-2021; AAJ-8097-2021Item Incidence and Outcome of Occult Uterine Sarcoma: A Multi-Centre, Retrospective Study of 18604 Operations Performed for Presumed Uterine Leiomyoma(2019) Yorganci, A; Meydanli, M. M.; Kadioglu, N.; Sahin, H.; Kayikcioglu, F.; Taskin, S.; Atasoy, L.; Akgul, M. A.; Kinay, T.; Tapisiz, O. L.; Haberal, N.; Evliyaoglu, O.; Tekin, O. Moraloglu; Ortac, F.; Ayhan, A.; https://orcid.org/0000-0001-9852-9911; AEY-5060-2022; AAK-4587-2021; AAJ-5802-2021Item Increased Level of Serum Cholesterol and Apoptosis Together Induces the Development of Liver Fibrosis and Early Allograft Loss(2020) Ozdemir, B. H.; Ozgun, G.; Soy, E. H. Ayvazoglu; Haberal, N.; Haberal, M.; 0000-0002-0993-9917; 0000-0001-9852-9911; 0000-0002-7528-3557; 0000-0002-3462-7632; AAC-5566-2019; AAK-4587-2021; X-8540-2019; AAJ-8097-2021Item Increased Level of Serum Cholesterol and Apoptosis Together Induces The Development of Liver Fibrosis and Early Allograft Loss(2021) Ozdemir, B. H.; Ozgun, G.; Soy, Ayvazoglu E. H.; Haberal, N.; Haberal, M.; https://orcid.org/0000-0002-7528-3557; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; X-8540-2019; AAC-5566-2019; AAJ-8097-2021Item A Single Centre Retrospective Clinicopathologic Study of Endomyocardial Biopsies After Heart Transplantation at Baskent University Hospital in Ankara 1993-2014(2014) Terzi, A.; Sezgin, A.; Tunca, M. Z.; Deniz, E.; Ayva, E. S.; Haberal, N.; Muderrisoglu, H.; Ozdemir, B. H.; https://orcid.org/0000-0002-1225-1320; https://orcid.org/0000-0001-9852-9911; https://orcid.org/0000-0002-9635-6313; https://orcid.org/0000-0002-7528-3557; F-7546-2013; AAK-4587-2021; AAG-8233-2020; X-8540-2019Item Surgical management and outcomes of metastatic tumors to the ovaries(2019) Rahatli, S.; Akilli, H.; Haberal, N.; Altundag, O.; Haberal, A.; Ayhan, A.Purpose of Investigation: Gynecologic and non-gynecologic tumors occasionally metastasize to the ovaries. Aim of this study was to describe the clinicopathologic characteristics and survival outcomes of patients with metastatic tumors to the ovaries. Materials and Methods: Between 2007-2017, 859 operations were performed in this center with initial diagnosis of ovarian mass. Seventy-five patients who had metastatic tumor to the ovaries in pathological examination were included the study. Results: Median overall survival of all patients was 26 +/- 5.9 months, three-year survival was 62%, and five-year survival was 37%. Patients who developed metachronous metastasis had better survival than patients who had synchronous metastasis (p = 0.05). Bilateral ovarian involvement was related with poor survival compared with unilateral involvement. Chemotherapy had beneficial effect on overall survival. Median survival in extensive surgery group was 30.9 months and it was better than minimal surgery group with 15.6 months, however it was not statistically significant (p= 0.973). Conclusion: The prognosis of the metastatic tumors to the ovaries is poor but achieving a complete resection and optimal debulking surgery may improve survival in some histologic subgroups.